Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palatability of Brensocatib Oral Liquid Formulations
NCT06178783Phase 1Completed
- Sponsor
- Insmed Incorporated
- Start
- Dec 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of brensocatib in Non-cystic fibrosis bronchiectasis (NCFB) (4 arms), sponsored by Insmed Incorporated. Primary endpoint: Number of Participants With High Acceptability to Each Brensocatib Formulation Based on Palatability Assessments Measured by the 9-point Hedonic Scale at Day 1. Started Dec 2023; status: completed.
02
Drugs
brensocatib
03
Conditions
Non-cystic fibrosis bronchiectasis (NCFB)
Beyond the preview
Go deeper on NCT06178783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06178783.